First competitive read-out of the peptide vaccine. Does that imply there could be more to follow? If you have a read of page one of the July 27, 2018 announcement below, the company highlighted this opening paragraph...
"Phylogica’s peptide vaccine program continues to produce encouraging in vivo data and has now been expanded beyond oncology to include viral illnesses that can be treated via the same vaccination strategy (T cell expansion and effector function)."
"Beyond oncology" via the same vaccination strategy.
And on the last paragraph...
"The peptide vaccine program continues to progress in the context of multiple different antigens (cargoes) and disease indications towards its ultimate read-out of complementarity to existing therapies in each of these indications to demonstrate improved treatment efficacy."
"multiple different antigens (cargoes) and disease indications"
So not only was the Phylomer vaccine able to slow tumour growth, but it also increased survival in an aggressive tumour model - melanoma.
Look at the graph on the recent conference poster. Note, these were only using their first generation CPPs as a few have already highlighted. Second generation CPPs have even greater CPP activity.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)